Jasper Therapeutics Statistics
 Total Valuation
 JSPR has a market cap or net worth of $58.64 million. The enterprise value is $20.45 million.
   Important Dates
 The next estimated earnings date is Friday, November 7, 2025, before market open.
 | Earnings Date  | Nov 7, 2025 | 
| Ex-Dividend Date  | n/a | 
  Share Statistics
 JSPR has 27.92 million shares outstanding. The number of shares has increased by 19.90% in one year.
 | Current Share Class  | 27.92M | 
| Shares Outstanding  | 27.92M | 
| Shares Change (YoY)  | +19.90% | 
| Shares Change (QoQ)  | +2.08% | 
| Owned by Insiders (%)  | 1.19% | 
| Owned by Institutions (%)  | 37.68% | 
| Float  | 23.67M | 
   Valuation Ratios
  | PE Ratio  | n/a | 
| Forward PE  | n/a | 
| PS Ratio  | n/a | 
| Forward PS  | n/a | 
| PB Ratio  | 1.57 | 
| P/TBV Ratio  | 2.46 | 
| P/FCF Ratio  | n/a | 
| P/OCF Ratio  | n/a | 
| PEG Ratio  | n/a | 
 Financial Ratio History  Enterprise Valuation
  | EV / Earnings  | n/a | 
| EV / Sales  | n/a | 
| EV / EBITDA  | n/a | 
| EV / EBIT  | n/a | 
| EV / FCF  | n/a | 
  Financial Position
 The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.09.
 | Current Ratio  | 2.10 | 
| Quick Ratio  | 1.93 | 
| Debt / Equity  | 0.09 | 
| Debt / EBITDA  | n/a | 
| Debt / FCF  | n/a | 
| Interest Coverage  | n/a | 
   Financial Efficiency
 Return on equity (ROE) is -146.87% and return on invested capital (ROIC) is -91.65%.
 | Return on Equity (ROE)  | -146.87% | 
| Return on Assets (ROA)  | -73.30% | 
| Return on Invested Capital (ROIC)  | -91.65% | 
| Return on Capital Employed (ROCE)  | -362.21% | 
| Revenue Per Employee  | n/a | 
| Profits Per Employee  | -$1.42M | 
| Employee Count | 64 | 
| Asset Turnover  | n/a | 
| Inventory Turnover  | n/a | 
  Taxes
  | Income Tax  | n/a | 
| Effective Tax Rate  | n/a | 
  Stock Price Statistics
 The stock price has decreased by -90.10% in the last 52 weeks. The beta is 2.80, so JSPR's price volatility has been higher than the market average.
 | Beta (5Y)  | 2.80 | 
| 52-Week Price Change  | -90.10% | 
| 50-Day Moving Average  | 2.50 | 
| 200-Day Moving Average  | 4.20 | 
| Relative Strength Index (RSI)  | 35.46 | 
| Average Volume (20 Days)  | 373,879 | 
  Short Selling Information
 The latest short interest is 1.55 million, so 5.54% of the outstanding shares have been sold short.
 | Short Interest  | 1.55M | 
| Short Previous Month  | 1.51M | 
| Short % of Shares Out  | 5.54% | 
| Short % of Float  | 6.54% | 
| Short Ratio (days to cover)  | 3.32 | 
  Income Statement
  | Revenue  | n/a | 
| Gross Profit  | n/a | 
| Operating Income  | -94.05M | 
| Pretax Income  | -90.92M | 
| Net Income  | -90.92M | 
| EBITDA  | -92.73M | 
| EBIT  | -94.05M | 
| Earnings Per Share (EPS)  | -$6.02 | 
 Full Income Statement  Balance Sheet
 The company has $39.51 million in cash and $2.16 million in debt, giving a net cash position of $37.36 million or $1.34 per share.
 | Cash & Cash Equivalents  | 39.51M | 
| Total Debt  | 2.16M | 
| Net Cash  | 37.36M | 
| Net Cash Per Share  | $1.34 | 
| Equity (Book Value)  | 23.50M | 
| Book Value Per Share  | 1.45 | 
| Working Capital  | 22.47M | 
 Full Balance Sheet  Cash Flow
 In the last 12 months, operating cash flow was -$73.48 million and capital expenditures -$377,000, giving a free cash flow of -$73.86 million.
 | Operating Cash Flow  | -73.48M | 
| Capital Expenditures  | -377,000 | 
| Free Cash Flow  | -73.86M | 
| FCF Per Share  | -$2.64 | 
 Full Cash Flow Statement  Margins
  | Gross Margin  | n/a | 
| Operating Margin  | n/a | 
| Pretax Margin  | n/a | 
| Profit Margin  | n/a | 
| EBITDA Margin  | n/a | 
| EBIT Margin  | n/a | 
| FCF Margin  | n/a | 
  Dividends & Yields
 JSPR does not appear to pay any dividends at this time.
 | Dividend Per Share  | n/a | 
| Dividend Yield  | n/a | 
| Dividend Growth (YoY)  | n/a | 
| Years of Dividend Growth  | n/a | 
| Payout Ratio  | n/a | 
| Buyback Yield  | -19.90% | 
| Shareholder Yield  | -19.90% | 
| Earnings Yield  | -157.30% | 
| FCF Yield  | -127.78% | 
    Analyst Forecast
 The average price target for JSPR is $28.00, which is 1,233.33% higher than the current price. The consensus rating is "Buy".
 | Price Target  | $28.00 | 
| Price Target Difference  | 1,233.33% | 
| Analyst Consensus  | Buy | 
| Analyst Count  | 11 | 
| Revenue Growth Forecast (5Y)  | n/a | 
| EPS Growth Forecast (5Y)  | -22.42% | 
 Stock Forecasts  Fair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value  | n/a | 
| Lynch Upside  | n/a | 
| Graham Number  | n/a | 
| Graham Upside  | n/a | 
  Stock Splits
 The last stock split was on January 4, 2024. It was a reverse split with a ratio of 1:10.
 | Last Split Date  | Jan 4, 2024 | 
| Split Type  | Reverse | 
| Split Ratio  | 1:10 | 
  Scores
  | Altman Z-Score  | n/a | 
| Piotroski F-Score  | 1 |